CoLucid Pharmaceuticals, Inc. is a Phase III clinical-stage biopharmaceutical company. The Company is engaged in developing a small molecule for the acute treatment of migraine headaches. Its product candidates address the needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those dissatisfied with existing therapies. Lasmiditan, the Company's lead product candidate, is an oral tablet for the acute treatment of migraine in adults. Lasmiditan selectively targets 5-HT1F receptors expressed in the trigeminal pathway in the central nervous system (CNS). Lasmiditan is designed to penetrate the CNS and block the pathway that contributes to headache pain. It is developing IV lasmiditan for the acute treatment of headache pain associated with migraine in adults, to be used in emergency rooms and urgent care settings. The Company is conducting its Phase III randomized, double-blind, placebo-controlled clinical trial of lasmiditan.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolNASDAQ:CLCD
CUSIPN/A
Phone+1-781-3652596
Debt
Debt-to-Equity RatioN/A
Current Ratio11.31
Quick Ratio11.30
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on Equity-83.51%
Return on Assets-70.62%
Miscellaneous
Employees7
Outstanding Shares19,280,000
CoLucid Pharmaceuticals (NASDAQ:CLCD) Frequently Asked Questions
What is CoLucid Pharmaceuticals' stock symbol?
CoLucid Pharmaceuticals trades on the NASDAQ under the ticker symbol "CLCD."
How were CoLucid Pharmaceuticals' earnings last quarter?
CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) released its quarterly earnings results on Wednesday, November, 9th. The biopharmaceutical company reported ($0.79) earnings per share for the quarter, meeting the consensus estimate of ($0.79). View CoLucid Pharmaceuticals' Earnings History.
When did CoLucid Pharmaceuticals IPO?
(CLCD) raised $55 million in an initial public offering (IPO) on Wednesday, May 6th 2015. The company issued 5,500,000 shares at $10.00 per share. Piper Jaffray and Stifel acted as the underwriters for the IPO and William Blair was co-manager.
Has CoLucid Pharmaceuticals been receiving favorable news coverage?
News headlines about CLCD stock have trended somewhat positive recently, according to Accern Sentiment. The research group ranks the sentiment of press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. CoLucid Pharmaceuticals earned a media sentiment score of 0.09 on Accern's scale. They also assigned news coverage about the biopharmaceutical company an impact score of 46.40 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.
How do I buy shares of CoLucid Pharmaceuticals?
Shares of CLCD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is CoLucid Pharmaceuticals' stock price today?
One share of CLCD stock can currently be purchased for approximately $46.5250.
How big of a company is CoLucid Pharmaceuticals?
CoLucid Pharmaceuticals has a market capitalization of $895.94 million. CoLucid Pharmaceuticals employs 7 workers across the globe.
How can I contact CoLucid Pharmaceuticals?
CoLucid Pharmaceuticals' mailing address is 222 3rd St, CAMBRIDGE, MA 02142-1102, United States. The biopharmaceutical company can be reached via phone at +1-781-3652596.
MarketBeat Community Rating for CoLucid Pharmaceuticals (CLCD)
MarketBeat's community ratings are surveys of what our community members think about CoLucid Pharmaceuticals and other stocks. Vote "Outperform" if you believe CLCD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLCD will underperform the S&P 500 over the long term. You may vote once every thirty days.
